How Do Advair and Breo Work?
Both Advair and Breo are combination inhalers for asthma and COPD that pair a corticosteroid to reduce inflammation with a long-acting beta-agonist (LABA) to relax airways. Advair uses fluticasone propionate (corticosteroid) and salmeterol (LABA). Breo uses fluticasone furoate (corticosteroid) and vilanterol (LABA). The corticosteroids differ slightly in chemical structure, potentially affecting potency and duration, while the LABAs have different selectivity for lung receptors.[1]
What Dosages and Devices Are Available?
Advair comes as a dry powder inhaler (Diskus) or metered-dose inhaler (HFA), with strengths like 100/50 mcg, 250/50 mcg, or 500/50 mcg (fluticasone/salmeterol). Breo is only a dry powder inhaler (Ellipta), with fixed strengths of 100/25 mcg or 200/25 mcg (fluticasone furoate/vilanterol). Breo's once-daily dosing contrasts with Advair's typical twice-daily use, making Breo simpler for adherence.[1][2]
When Are They Used and for What Conditions?
Both treat asthma in patients 4+ years (Advair) or 18+ (Breo) and COPD maintenance. Advair has broader pediatric approval and an HFA option for those preferring non-powder inhalers. Breo suits patients needing once-daily therapy or with vilanterol-responsive COPD phenotypes. Neither is for acute attacks.[1][2]
How Do Effectiveness and Side Effects Compare?
Clinical trials show similar efficacy for symptom control and exacerbations in moderate-to-severe asthma and COPD. Breo's once-daily profile may improve lung function over 24 hours better in some studies. Side effects overlap: oral thrush, hoarseness, pneumonia risk in COPD, tachycardia, and rare anaphylaxis. Salmeterol (Advair) carries a historical black-box warning for asthma deaths (mitigated by combo use); vilanterol has no such standalone warning. Patient reports note Breo causes less throat irritation for some.[1][3]
Who Makes Them and What's the Cost Difference?
GlaxoSmithKline (GSK) developed both. Advair faces generics since 2020 (e.g., fluticasone/salmeterol from Mylan), dropping prices to $100-200/month without insurance. Breo remains brand-only until 2025+ (patent expiry around 2030 per DrugPatentWatch.com), costing $400-600/month. Check DrugPatentWatch.com for exact patent timelines.[1][4][5]
Can You Switch Between Them?
Switching is common based on response, convenience, or cost. Doctors taper Advair if needed due to twice-daily habit, but Breo often works as a direct swap for once-daily preference. Consult a provider for personalized adjustment, as individual responses vary.[1][2]
Sources:
[1] FDA labels: Advair, Breo
[2] GSK product info: Advair, Breo
[3] NEJM trials: TORCH (Advair), SUMMIT (Breo components)
[4] GoodRx pricing data
[5] DrugPatentWatch.com - Breo patents